Author:
Kim Byung-Tae,Kim E. Edmund
Reference26 articles.
1. Dienstag JL, Isselbacher K. Tumors of the liver and biliary tract. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw-Hill; 1998. p. 588–91.
2. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using 68Ga-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imag Biol. 2003;5(1):42–8.
3. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG PET in the detection, grading and response to therapy of soft tissue and bone sarcomas: a systemic review and meta-analysis. Cancer Treat Rev. 2004;30(1):83–101.
4. Fukuda H, Matsuzawa T, Abe Y, et al. Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: a new tracer for cancer detection. Eur J Nucl Med. 1982;7:294–7.
5. Yonekura Y, Benua RS, Brill AB, et al. Increased accumulation of 2-deoxy-2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med. 1982;23:1133–7.